Suicidal overdose of dolutegravir: A case report
Southern African Journal of HIV Medicine
Field | Value | |
Title | Suicidal overdose of dolutegravir: A case report | |
Creator | Daimari, Rahul Kwape, Lawrence Oyekunle, Anthony A. | |
Description | Dolutegravir (DTG) is the most recently introduced integrase inhibitor for the treatment of HIV infection and is preferred for its superior tolerability and efficacy in both new and pre-treated patients, and infrequent drug interactions. Since January 2017, Botswana has adopted a ‘treat-all’ approach with a DTG-based antiretroviral (ARV) regimen as first-line treatment. We report a 29-year-old man with clinical stage 1 HIV infection who had been started on DTG, tenofovir and emtricitabine eight months prior, and who was admitted following a suicidal overdose of 1500 mg of DTG. He reported only minor symptoms including vomiting, epigastric pain and dizziness; which promptly resolved following supportive treatment. On admission, full blood count, liver function tests and electrocardiography were unremarkable. However, there was a non-progressive increase in serum creatinine. After a month off ARVs, he was successfully restarted on antiretroviral therapy without any serious adverse effect. | |
Publisher | AOSIS | |
Date | 2018-06-18 | |
Identifier | 10.4102/sajhivmed.v19i1.799 | |
Source | Southern African Journal of HIV Medicine; Vol 19, No 1 (2018); 3 pages 2078-6751 1608-9693 | |
Language | eng | |
Relation |
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:
https://sajhivmed.org.za/index.php/hivmed/article/view/799/1198
https://sajhivmed.org.za/index.php/hivmed/article/view/799/1197
https://sajhivmed.org.za/index.php/hivmed/article/view/799/1199
https://sajhivmed.org.za/index.php/hivmed/article/view/799/1190
|
|
ADVERTISEMENT